NCT04513366

URI: https://gptkb.org/entity/NCT04513366

GPTKB entity

Predicate	Object
gptkbp:instanceOf	gptkb:clinical_trial
gptkbp:ageRange	16 years and older
gptkbp:clinicalTrialPhase	Phase 3
gptkbp:clinicalTrialsGovURL	https://clinicaltrials.gov/ct2/show/NCT04513366
gptkbp:collaboratesWith	gptkb:Pfizer
gptkbp:completedIn	May 2, 2023
gptkbp:condition	gptkb:COVID-19
gptkbp:enrollment	44000
gptkbp:gender	All
https://www.w3.org/2000/01/rdf-schema#label	NCT04513366
gptkbp:intervention	gptkb:Placebo gptkb:BNT162b2 Parallel Assignment
gptkbp:location	gptkb:Argentina gptkb:Brazil gptkb:Germany gptkb:South_Africa gptkb:Turkey gptkb:United_States
gptkbp:mask	Double
gptkbp:officialName	A Phase 1/2/3, Placebo-controlled, Randomized, Observer-blind, Dose-finding Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of SARS-CoV-2 RNA Vaccine Candidates Against COVID-19 in Healthy Individuals
gptkbp:principalInvestigator	gptkb:Stephen_J._Thomas,_MD
gptkbp:purpose	Prevention
gptkbp:result	Efficacy of BNT162b2 against confirmed COVID-19 Safety and tolerability of BNT162b2
gptkbp:sponsor	gptkb:BioNTech_SE
gptkbp:startDate	July 27, 2020
gptkbp:studyType	Interventional
gptkbp:bfsParent	gptkb:SEL-212
gptkbp:bfsLayer	6